Literature DB >> 16213361

Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma.

Fabio Nunes1, Yiping Shen, Yo Niida, Roberta Beauchamp, Anat O Stemmer-Rachamimov, Vijaya Ramesh, James Gusella, Mia MacCollin.   

Abstract

The molecular basis of tumorigenesis and tumor progression in meningiomas is not fully understood. The neurofibromatosis 2 (NF2) locus is inactivated in 50-60% of sporadic meningiomas, but the genetic basis of sporadic meningiomas not inactivated at the NF2 locus remains unclear. Specifically, there is conflicting data regarding the role of the tumor suppressor gene DAL-1/4.1B. Using microsatellite markers, we studied 63 sporadic meningiomas to determine loss of heterozygosity (LOH) at the NF2 and DAL-1/4.1B loci. Array comparative genomic hybridization analysis of 52 of these tumors was performed to determine copy number changes on chromosomes 18 and 22. Forty-one of 62 informative tumors showed LOH at the NF2 locus (66%) while only 12 of 62 informative tumors (19%) showed LOH of DAL-1/4.1B. Eleven of 12 (92%) tumors with DAL-1/4.1B LOH also had NF2 LOH. Monosomy or large deletions of chromosomes 18 and 22 were the main mechanism for LOH in these tumors. These studies implicate the DAL-1/4.1B locus in sporadic meningiomas less commonly than reported previously, and suggest that it is a progression rather than an initiation locus. Furthermore, we found the majority of meningiomas developed monosomy rather than isodisomy at the NF2 and DAL-1/4.1B loci as the mechanism for LOH.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16213361     DOI: 10.1016/j.cancergencyto.2005.04.003

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  17 in total

1.  Merlin/NF2 Suppresses Pancreatic Tumor Growth and Metastasis by Attenuating the FOXM1-Mediated Wnt/β-Catenin Signaling.

Authors:  Ming Quan; Jiujie Cui; Tian Xia; Zhiliang Jia; Dacheng Xie; Daoyan Wei; Suyun Huang; Qian Huang; Shaojiang Zheng; Keping Xie
Journal:  Cancer Res       Date:  2015-10-19       Impact factor: 12.701

Review 2.  Advances in meningioma genetics: novel therapeutic opportunities.

Authors:  Matthias Preusser; Priscilla K Brastianos; Christian Mawrin
Journal:  Nat Rev Neurol       Date:  2018-01-05       Impact factor: 42.937

3.  Cellular prion protein (PrPC) in the development of Merlin-deficient tumours.

Authors:  L Provenzano; Y Ryan; D A Hilton; J Lyons-Rimmer; F Dave; E A Maze; C L Adams; R Rigby-Jones; S Ammoun; C O Hanemann
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

Review 4.  Tumor suppressor role of protein 4.1B/DAL-1.

Authors:  Zi Wang; Ji Zhang; Mao Ye; Min Zhu; Bin Zhang; Mridul Roy; Jing Liu; Xiuli An
Journal:  Cell Mol Life Sci       Date:  2014-09-03       Impact factor: 9.261

5.  Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation.

Authors:  K Adam Morrow; Shamik Das; Brandon J Metge; Keqiang Ye; Madhuri S Mulekar; J Allan Tucker; Rajeev S Samant; Lalita A Shevde
Journal:  J Biol Chem       Date:  2011-09-30       Impact factor: 5.157

Review 6.  Meningiomas and Proteomics: Focus on New Potential Biomarkers and Molecular Pathways.

Authors:  Rosaria Viola Abbritti; Francesca Polito; Maria Cucinotta; Claudio Lo Giudice; Maria Caffo; Chiara Tomasello; Antonino Germanò; Mohammed Aguennouz
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

Review 7.  Spinal cord tumours: advances in genetics and their implications for treatment.

Authors:  Patricia L Zadnik; Ziya L Gokaslan; Peter C Burger; Chetan Bettegowda
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

8.  Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.

Authors:  Okay Saydam; Yiping Shen; Thomas Würdinger; Ozlem Senol; Elvan Boke; Marianne F James; Bakhos A Tannous; Anat O Stemmer-Rachamimov; Ming Yi; Robert M Stephens; Cornel Fraefel; James F Gusella; Anna M Krichevsky; Xandra O Breakefield
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

9.  A role for the p53 pathway in the pathology of meningiomas with NF2 loss.

Authors:  ZeNan Chang; Chin-Lin Guo; Iris Ahronowitz; Anat O Stemmer-Rachamimov; Mia MacCollin; Fabio P Nunes
Journal:  J Neurooncol       Date:  2008-11-01       Impact factor: 4.130

10.  Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas.

Authors:  Yiping Shen; Fabio Nunes; Anat Stemmer-Rachamimov; Marianne James; Gayatry Mohapatra; Scott Plotkin; Rebecca A Betensky; David A Engler; Jennifer Roy; Vijaya Ramesh; James F Gusella
Journal:  BMC Med Genomics       Date:  2009-07-09       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.